Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 7/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 7/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30568367 | 1.00 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL21494483 | 1.00 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL30568373 | 1.00 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL3558885 | 1.00 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DLMNA | |
| Hydrochloric Acid SCHEMBL30568368 | 0.99 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DLMNA | |
| Hydrochloric Acid SCHEMBL21494477 | 0.99 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DLMNA | |
| Hydrochloric Acid SCHEMBL21494486 | 0.99 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DLMNA | |
| Hydrochloric Acid SCHEMBL7746561 | 0.99 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DLMNA | |
| Hydrochloric Acid SCHEMBL30568376 | 0.99 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL2993092 | 0.95 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767295-B2 | Isoindole derivative | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2023-09-26 | — | — | US | disclosed |
| US-20210155590-A1 | ISOINDOLE DERIVATIVE | TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) | 2021-05-27 | — | — | US | disclosed |
| EP-3782983-A1 | ISOINDOLE DERIVATIVE | Tianjin Hemay Pharmaceutical Co., Ltd. (CN) | 2021-02-24 | — | — | EP | disclosed |
| CN-107698484-B | Preparation method and application of lenalidomide derivative | 广东中科药物研究有限公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-110386893-A | Isoindole derivatives | 天津合美医药科技有限公司 | 2019-10-29 | — | — | CN | disclosed |
| WO-2019201255-A1 | ISOINDOLE DERIVATIVE | 天津合美医药科技有限公司 | 2019-10-24 | — | — | WO | disclosed |
| CN-107698484-A | A kind of preparation method of derivative of lenalidomide and application | 广东中科药物研究有限公司 | 2018-02-16 | — | — | CN | disclosed |
| EP-2083011-B1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | TIANJIN HEMAY BIO TECH CO LTD (CN) | 2014-06-04 | — | — | EP | disclosed |
| EP-1605896-B1 | 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8466191-B2 | Pyrroline derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof | ZHANG HESHENG (CN) | 2013-06-18 | — | — | US | disclosed |
| US-20100179189-A1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | ZHANG HESHENG | 2010-07-15 | — | — | US | disclosed |
| EP-2083011-A1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2009-07-29 | — | — | EP | disclosed |
| EP-1605896-A2 | 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004080423-A2 | 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |
| EP-0862552-B1 | SUCCINIMIDE AND MALEIMIDE CYTOKINE INHIBITORS | CELGENE CORP (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-0942902-A2 | NOVEL IMMUNOTHERAPEUTIC IMIDES/AMIDES | CELGENE CORPORATION (US) | 1999-09-22 | — | — | EP | disclosed |
| EP-0862552-A1 | SUCCINIMIDE AND MALEIMIDE CYTOKINE INHIBITORS | CELGENE CORPORATION (US) | 1998-09-09 | — | — | EP | disclosed |
| WO-1998024763-A2 | IMMUNOTHERAPEUTIC IMIDES/AMIDES AS PDE IV AND TNF INHIBITORS | CELGENE CORPORATION (US) | 1998-06-11 | — | — | WO | disclosed |
| US-5703098-A | INHIBITORS OF CYTOKINES INCLUDING TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-30 | — | — | US | disclosed |
| WO-1997012859-A1 | SUCCINIMIDE AND MALEIMIDE CYTOKINE INHIBITORS | CELGENE CORPORATION (US) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767295-B2 | Isoindole derivative | COX4I1, ALDH1A2, GDI2 | PDE4A 1740/4885PDE4B 1378/4885PDE4C 2317/4885 |
| US-20100179189-A1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | TNF, IL1B, NOS1 | PDE4A 2306/4885PDE4B 2498/4885PDE4C 2510/4885 |
| US-20210155590-A1 | ISOINDOLE DERIVATIVE | COX4I1, ALDH1A2, GDI2 | PDE4A 1740/4885PDE4B 1378/4885PDE4C 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.